# Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

> **NCT03222856** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 44 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT03222856
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2018-10-31
- **Final completion:** 2020-12-23
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222856, "Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03222856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*